MiRXES is a biotechnology company focused on improving and saving lives with RNA-powered disease early detection tests.
MiRXES' mission is to save lives through early, actionable, and personalized diagnoses.
MiRXES was founded in 2014 as a spin-off from A*STAR by Zhou Lihan, Zou Ruiyang, and Too Heng-Phon. The company is headquartered in Singapore, with operations in China, Japan and the United States.
MiRXES launched GASTROClear, the world’s first microRNA blood test for early detection of gastric cancer. The MiRXES’s multi-cancer early detection pipeline includes screening tests for lung, colorectal, liver, and breast cancer.
MiRXES' ID3EAL discovery tool and workflow has been adopted by top academic and industry partners globally and is backed by the world’s first industry standard for microRNA-base diagnostics.
MiRXES worked closely with A*STAR, Diagnostics Development Hub (DxD) and Tan Tock Seng Hospital (TTSH) to mass produce Fortitude Kit, Singapore’s first authorised COVID-19 RT-PCR test. Since February 2020, more than 7 million Fortitude Kits have been deployed globally.
MiRXES is backed by CR-CP Life Science Fund, Rock Springs Capital, EDBI, CCBI, Keytone Ventures, and others. The company raised $77M in Series C round on Jul 08, 2021. This brings MiRXES' total funding to $120M to date. The new round valued the company at $500M post-money.